Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Cetrorelix acetate (drug) — also listed as: Cetrotide®
• Cetrorelix acetate (drug) — also listed as: Cetrotide®
• Recombinant Human Choriogonadotropin (r-hCG) (drug) — also listed as: Ovitrelle®
• Recombinant human follicle stimulating hormone (r-hFSH) (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Research Site
  Toulouse, France
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Traditional intervention for HH using HCG and FSH (drug) — also listed as: Tranditional
• Sequential intervention for HH using HCG and FSH (drug) — also listed as: Sequential
• Sequential intervention for HH using HCG and FSH plus zinc (drug) — also listed as: Sequential plus

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
  Shanghai, Shanghai Municipality, China
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• r-hFSH (drug) — also listed as: Gonal-f®
• r-hLH (drug) — also listed as: LHadi®
• u-hCG (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Royal University Hospital
  Saskatoon, Saskatchewan, Canada
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• hCG 1500 IU three times a week (drug) — also listed as: Pregnyl (Organon) ampule 1500 IU
• Pregnyl (hCG) ampule 1500 IU/three times a week (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Gulhane School of Medicine Dep. of Endocrinology and Metabolism
  Ankara, Turkey (Türkiye)
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Leuveris (drug)
• Leuveris (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Poriya hospital
  Tiberias, Israel
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Gonal -f® [r-hFSH] (drug) — also listed as: Gonal-f®, Follitropin Alfa
• Ovitrelle® [r-hCG alfa] (drug) — also listed as: Ovitrelle®, Ovidrel®
• Gonadotropin-releasing hormone (GnRH) Agonist (drug)
• Gonadotropin-releasing hormone (GnRH) Antagonist (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Research Site
  Paris, France
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• triptorelin (drug) — also listed as: triptorelin: Diphereline
• hCG (drug)
• hCG (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University
  Guangzhou, Guangdong, China
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH) (drug) — also listed as: r-hLH, r-hFSH
• r-hFSH (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Merck Serono S.p.A.
  Roma, Italy
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Recombinant human luteinizing hormone (r-hLH) (drug) — also listed as: Luveris (r-hLH)
• Recombinant human follicle-stimulating hormone (r-hFSH) (drug) — also listed as: Gonal-F (r-hFSH)
• Human chorionic gonadotropin (hCG) (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Peking Union Medical College Hospital
  Beijing, China
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• recombinant FSH (Puregon, Organon, The Netherlands) (drug)
• GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands) (drug)
• hCG (Pregnyl, Organon, The Netherlands) (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Eugonia
  Athens, Greece
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Follitropin alfa injected by Pen device (device) — also listed as: Gonal-f®
• Recombinant Human Choriogonadotropin (r-hCG) (device) — also listed as: Ovidrel®, Choriogonadotropin alfa

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

The registry does not list facilities in this record. This does not mean the study has no sites.

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Buserelin and Pregnyl (drug)
• Pregnyl (drug)
• Buserelin and Pregnyl (drug)
• Pregnyl (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• The Fertility Clinic, Regional Hospital of Skive
  Skive, Denmark
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• recombinant luteinizing hormone (r-LH) (drug)
• recombinant human chorionic gonadotropin (r-hCG) (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Fertility Clinic Skive regional Hospital
  Skive, Denmark
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• human chorionic gonadotrophin (drug) — also listed as: choriomon

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Cairo University
  Cairo, Egypt
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Ovulation induction with choriogonadotropin alfa (drug)
• Aspiration of the dominant follicle (procedure)
• Control (other)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• University of Sao Paulo General Hospital
  São Paulo, São Paulo, Brazil
  Site recruitment: Recruiting

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• r-hCG (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Cha Medical school Boondang-Cha hospital
  Seongnam, Gyeong-Gi Do, South Korea
  Site recruitment: Not reported
• Cha Medical school Gangnam-Cha hospital
  Seoul, South Korea
  Site recruitment: Not reported
• Kwandong university medical school Cheil hospital
  Seoul, South Korea
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Luveris® 75 IU (drug) — also listed as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH)
• Luveris® 25 IU (drug) — also listed as: Lutropin alfa, Recombinant human luteinizing hormone (r-hLH)
• Placebo (drug)
• Recombinant human follicle stimulating hormone (r-hFSH) (drug) — also listed as: Follitropin alfa
• Recombinant human chorionic gonadotropin (r-hCG) (drug) — also listed as: Choriogonadotropin alfa

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• U.S. Medical Information, 1-888-275-7376
  Rockland, Massachusetts, United States
  Site recruitment: Not reported

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Choriogonadotropin alpha (r-hCG) (drug) — also listed as: Ovidrel

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

The registry does not list facilities in this record. This does not mean the study has no sites.

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

• Coenzyme Q10 (drug) — also listed as: CC 100 mg/day 2-6 and CoQ10,60 mg 3 times day orally on day 2 till hCG
• clomiphene citrate (drug)

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

• Mansoura University Hospitals
  Al Mansurah, Dakahlia Governorate, Egypt
  Site recruitment: Not reported